The CRO Airdrop Campaign is live 🚨Opt in and net buy US$20+ of $CRO during the campaign period to secure your share of the US$212,000 $CRO prize pool 🎉Guaranteed rewards for every eligible participant 🎁🗓️ Now - 2 SepNot available in all jurisdictions. Details + T&Cs 👇https://t.co/PQvrZxxKVJ@cronos_chain ...

Star Projects of #MEXC’s 0 Trading Fee Fest (Aug 27, 2025)!🏆 Top 3 Gainers:🏅 $CRO | @cronos_chain🥈 $CKB | @NervosNetwork🥉 $VINE | @rusNo trading fees, just pure gains!#MEXC0Fee ...

Core Viewpoint - The potential reclassification of marijuana from Schedule I to Schedule III by the Trump administration could significantly impact the cannabis industry, particularly for Tilray Brands, with projections indicating a possible doubling of revenues and substantial stock gains [2][10]. Revenue Growth Projections - The global legal marijuana market is expected to grow at a 25.4% CAGR, with Schedule III reclassification likely to enhance legitimacy, banking access, and institutional participation [4]. - Tilray's revenues could increase from $821 million to approximately $1.65 billion over three years due to multiple reform-related factors [5][10]. Valuation Multiple Expansion - Currently, Tilray trades at 1.8x trailing revenues, significantly lower than the broader market's 3.2x multiple, primarily due to regulatory uncertainty [7]. - A successful Schedule III reclassification could justify a valuation multiple expansion to 5.0x, aligning Tilray with peers like Cronos, which trades above 7x trailing revenues [7][13]. Growth Drivers - Key growth drivers include tax savings from the removal of Section 280E, improved banking access, interstate commerce opportunities, international expansion, and increased legitimacy of medical cannabis [6][10]. Target Valuation Scenario - The target valuation for Tilray could reach $8.25 billion based on projected revenues of $1.65 billion, representing an upside potential of over 400% from the current valuation of $1.6 billion [13].

The market is pulling back, which coin are you MOST bullish on right now?1️⃣ @JasmyMGT 91.9%2️⃣ @vechainofficial 88.6%3️⃣ @cronos_chain 81.9%4️⃣ @FartCoinOfSOL 67.9%5️⃣ SPX6900 83.5%6️⃣ @ethena_labs 80.9%7️⃣ @hedera 89.0%8️⃣ @AlgoFoundation 81.1%9️⃣ @Shibtoken 85.8%🔟 @NEARProtocol 86.4% ...

MEXC Trading Fee Fest Highlights - MEXC launched a "0 Trading Fee Fest" on August 5, 2025 [1] - The promotion emphasizes zero trading fees to maximize potential gains for users [1] Top Performing Assets - The top 3 gainers during the fest included NEIROETH (@neiro), CRO (@cronos_chain), and UNI (@Uniswap) [1]

Looks like the Don wants an Ice White card from Crypto dot comWonder how much lobbying money the spent…I haven’t heard the name Cronos in what feels like 4 yearsTylerD 🧙‍♂️ (@Tyler_Did_It):Truth Social just filed for its "Crypto Blue Chip ETF"And it will hold Bitcoin, ETH, SOL, XRP and CROWith a bigger CRO allocation than XRP https://t.co/K9BpseKu4a ...

Who invited Cronos to this party? https://t.co/8UbdWdTnGZ ...

Group 1: Company Overview - Altria's primary business involves selling nicotine products, with cigarettes constituting the majority of its revenue [2] - The company operates within the consumer staples sector, which typically includes products with consistent demand [2] Group 2: Financial Performance - Altria experienced a 13.7% year-over-year decline in cigarette volumes in the first quarter of 2025, indicating a continuing downward trend [4] - The company took a $900 million write-down in the first quarter to reduce the carrying value of its investment in NJOY due to a patent lawsuit [6] Group 3: Strategic Challenges - Altria has made multiple attempts to find alternative products to replace cigarettes, but these efforts have resulted in significant financial losses [5][9] - The company previously invested heavily in Juul and Cronos, both of which led to multi-billion-dollar write-downs and ultimately failed to deliver expected returns [8][9] Group 4: Investment Outlook - Despite a high dividend yield of 6.9%, the underlying business struggles raise concerns about the sustainability of this yield [1][10] - The lack of successful product replacements and ongoing challenges suggest that most investors may find the risk associated with Altria's stock to be unworthy [10]